Fernand Serrane

Cagent Vascular announces initial RECOIL Study results: Serranator demonstrates 49% less recoil than POBA in BTK arteries

Retrieved on: 
Tuesday, July 11, 2023
Health, FDA, Surgery, Health Technology, General Health, Clinical Trials, Biotechnology, CE, Clear, Amputation, Stanford University, PAD, Fernand Serrane, Elective surgery, BTK, Sale, Peripheral artery disease, Wound healing, Patient, Risk, Mortality, CLTI, Dilation, Dissection, Telescopic sight, Medical imaging, POBA, MD

Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study.

Key Points: 
  • Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study.
  • This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA).
  • The study results demonstrated that lesions treated using Serration Angioplasty exhibited 49% less average recoil than POBA.
  • “The 49% difference demonstrated in the RECOIL study between Serranator® and POBA is statistically significant and in my view also clinically relevant.

Cagent Vascular announces superior lumen gain, greater volumetric blood flow using Serration Angioplasty: A sub-analysis of the PRELUDE BTK study

Retrieved on: 
Tuesday, January 31, 2023
Health, Surgery, Health Technology, Clinical Trials, General Health, Biotechnology, Angioplasty, Physician, Journal, CLTI, Biomedicine, Patient, Dean (education), Biomedical engineering, Poiseuille, Amputation, Mount Sinai Medical Center, Death, PAD, Wound healing, UC, Peripheral artery disease, Serration, BTK, Quality of life, POBA, University of California, Irvine, Medical device, Fernand Serrane, Research

Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA).

Key Points: 
  • Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA).
  • The Serranator-treated lesions had an average final residual stenosis of 17.2 +/- (8.2%) versus 33.7 +/- (15.7%) in the POBA group.
  • The average balloon inflation pressure was 5 ATM in the Serranator group versus 9 ATM in the conventional balloon angioplasty group.
  • In these cases, our goal is to restore sufficient blood flow to allow a patient’s wound to heal, without leaving anything behind.

Cagent Vascular Announces Commercial Launch of the Serranator Above-the-Knee (ATK) Product

Retrieved on: 
Wednesday, June 1, 2022
General Health, Medical Devices, Health, Other Technology, Technology, Community, Life, Economic development, Elective surgery, Mount Sinai Hospital, Pressure, Standard of care, Artery, Dissection, CEO, Pennsylvania Department of Community and Economic Development, Physician, Sale, Cardiovascular disease, Patient, Technology, BTK, Adoption, ATK, MD, Economy, Angioplasty, Miriam Hospital, Pharmaceutical industry, Fernand Serrane

Cagent Vascular launched the Serranator Below-the-Knee (BTK) product in January 2021.

Key Points: 
  • Cagent Vascular launched the Serranator Below-the-Knee (BTK) product in January 2021.
  • Since then, there has been rapid adoption at targeted centers, where Serranator is quickly becoming the standard of care.
  • The Serranator PTA Serration Balloon Catheter is an angioplasty device with serrated metal strips embedded on a semi-compliant balloon.
  • Expanding into the ATK segment will generate significant incremental revenue and build upon our success from last years BTK product launch where the Serranator was used as the primary therapy.